Business
Cadrenal Therapeutics Provides Fiscal Year 2022 Corporate Update
PONTE VEDRA, Fla., March 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a
About this update from Cadrenal Therapeutics, Inc.
[{"type":"text","content":"PONTE VEDRA, Fla., March 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2022.\n\n \n \n \n \n \n \n\n \nRecent Highlights\nU.S. Food and Drug Administration (\"FDA\") granted Fast Track designation for tecarfarin for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation.Formed Scientific Advisory Board (SAB) in support of the development of tecarfarin for the prevention of systemic thromboembolism.Appointed Douglas Losordo as Chief Medical Officer, and Matthew Szot as Chief Financial Officer.Rang the Nasdaq closing bell on February 8, 2023.Completed an initial public offering (\"IPO\") raising gross proceeds of $7.0 million with the listing of its common shares on the Nasdaq Capital Market.\"Over the past year, we have taken significant steps to advance the development of tecarfarin, a novel therapy designed for the prevention of blood clots of cardiac origin in patients with end-stage renal disease and atrial fibrillation,\" commented Quang Pham, CEO of Cadrenal Therapeutics. \"Following our acquisition of the rights to tecarfarin in April 2022, we moved quickly to assemble a world-class group of anticoagulant, medical and scientific experts to provide strategic guidance to Cadrenal, and brought on key management team members to advance our mission. Earlier this year, we successfully received Fast Track designation from the U.S. FDA for tecarfarin and completed our initial public offering. We are currently planning a Phase 3 clinical trial for tecarfarin based on feedback previously received by the U.S. FDA. We look forward to working closely with the FDA to evaluate this therapy as a potential new treatment option for the severely underserved patient population that has end-stage renal disease and atrial fibrillation.\"\nTecarfarin \nTecarfarin, which has been granted orphan drug and Fast Track designations by the U.S. FDA, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with End-Stage Renal Disease (ESRD) and Atrial Fib...